Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers

(2011) C. Friedrich et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin

(2011) U. Graefe-Mody et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers

(2011) E.U. Graefe-Mody et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

(2010) J. J. Neumiller et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

(2010) Akiko Sarashina et al.   CLINICAL THERAPEUTICS

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired  -Cell Function?

(2010) J. J. Meier et al.   DIABETES

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

(2010) S. Del Prato et al.   DIABETES OBESITY & METABOLISM

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Assessment of the Pharmacokinetic Interaction between the Novel DPP-4 Inhibitor Linagliptin and a Sulfonylurea, Glyburide, in Healthy Subjects

(2010) Ulrike Graefe-Mody et al.   Drug Metabolism and Pharmacokinetics

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

(2009) Carolyn F. Deacon et al.   ADVANCES IN THERAPY

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events

(2009) Bo Ahrén   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats

(2009) Silke Retlich et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice

(2009) Dirk Reinhold et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

(2009) E. U. Graefe-Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

(2009) Holger Fuchs et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

(2008) A. J. Garber et al.   DIABETES OBESITY & METABOLISM

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS